Skip to main content

Table 13 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the Barthel Index, for the subgroup in Netherlands

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

 

EQ-5D-3L at 6 months (mean)

EQ-5D-3L at 12 months (mean)

Difference between 12 and 6 months EQ-5D-3L (95% CI)

Effect size (Cohen’s D)a

n

% reporting 3L score increase

Barthel Index

 Improved

0.79

0.88

0.09 (0.00 to 0.18)

0.58

11

55

 No change

0.87

0.90

0.02 (− 0.01 to 0.07)

0.22

37

41

 Worsened

0.69

0.63

− 0.03 (− 0.13 to 0.07)

− 0.10

15

40

 

EQ-5D-5L at 6 months (mean)

EQ-5D-5L at 12 months (mean)

Difference between 12 and 6 months EQ-5D-5L (95% CI)

Effect size (Cohen’s D)

n

% reporting 5L score increase

Barthel Index

 Improved

0.73

0.85

0.12 (0.02 to 0.22)

0.78

11

64

 No change

0.84

0.87

0.03 (− 0.01 to 0.08)

0.21

37

43

 Worsened

0.68

0.62

− 0.06 (− 0.15 to 0.03)

− 0.21

15

27

  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large